David Lawson, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (91 ratings)

Role

Medical Oncology
Specialty

Skin Cancer and Melanoma
Research Program

Discovery and Developmental Therapeutics
Practicing Since

1979

Call 404-778-0680

Background

A board certified medical oncologist, David H. Lawson, MD, specializes in the treatment of patients with melanoma or other cutaneous malignancies. Dr. Lawson's practice is located at Winship Cancer Institute of Emory University.

Dr. Lawson is a member of the Eastern Cooperative Oncology Group Melanoma Committee. He is a member of the American Society of Biological Therapy, the American Society for Clinical Oncology and the American Association for Cancer Research.

He earned his Medical Degree and completed his fellowship and residency at Emory University School of Medicine.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Medical Oncology, 1979
Emory University School of Medicine
Residency, Internal Medicine, 1977
Emory University School of Medicine
Internship, Internal Medicine, 1975
Emory University School of Medicine
Medical Education, MD, 1974
Emory University School of Medicine

Board Certifications

Medical Oncology
American Board of Internal Medicine, 1979
Internal Medicine
American Board of Internal Medicine, 1977

Professional Memberships

American Association for Cancer Research
American Society for Clinical Oncology
American Society of Biological Therapy

Research

View Current Clinical Trials


VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) Phase III Conditions Advanced Melanoma Location Winship Cancer Institute
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Phase II/III Conditions Advanced Melanoma Location Winship Cancer Institute
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Phase II Conditions Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Tregs protect against combination checkpoint blockade toxicity induced by Tph and B cell interactions. The Journal of clinical investigation	A Duffy, MI Azeem, S Kanangat, M Yushak, D Lawson, MV Dhodapkar, KM Dhodapkar	05/02/2024
Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy. JID innovations : skin science from molecules to population health	H Yeung, KJ Supapannachart, S Francois, CH Adler, RR Kudchadkar, DH Lawson, ML Yushak, AI Shariff, SC Chen	11/01/2023
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA dermatology	M Kashani-Sabet, SA Leachman, JA Stein, JL Arbiser, EG Berry, JT Celebi, C Curiel-Lewandrowski, LK Ferris, JM Grant-Kels, D Grossman, RP Kulkarni, MA Marchetti, KC Nelson, D Polsky, EV Seiverling, SM Swetter, H Tsao, A Verdieck-Devlaeminck, ML Wei, A Bar, EK Bartlett, JL Bolognia, TL Bowles, KB Cha, EY Chu, RI Hartman, EB Hawryluk, RM Jampel, L Karapetyan, M Kheterpal, DH Lawson, PD Leming, TN Liebman, ME Ming, D Sahni, SA Savory, SS Shaikh, AJ Sober, VK Sondak, N Spaccarelli, RP Usatine, S Venna, JM Kirkwood	05/01/2023
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report. Case reports in oncology	AR Cruse, AJ Basilio, DH Lawson	01/01/2023
Practical resiliency training for healthcare workers during COVID-19: results from a randomised controlled trial testing the Community Resiliency Model for well-being support. BMJ open quality	IM Duva, MK Higgins, M Baird, D Lawson, JR Murphy, L Grabbe	11/01/2022
Clinical Correlation between Acute Exudative Polymorphous Paraneoplastic Vitelliform Maculopathy and Metastatic Melanoma Disease Activity: A 48-month Longitudinal Case Report. Ocular immunology and inflammation	CM Mueller, SL Hojjatie, DH Lawson, N Jain, J Robinson, MK Khan, ML Yushak, G A Datoo O'Keefe	02/17/2022
Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition. Frontiers in oncology	HM Knochelmann, MB Ware, A Rali, S Linderman, JG Shantha, DH Lawson, M Yushak, R Swerlick, CM Paulos, S Yeh, R Kudchadkar	01/01/2022
Correlates of financial toxicity in adult cancer patients and their informal caregivers. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	G Sadigh, J Switchenko, KE Weaver, D Elchoufi, J Meisel, MA Bilen, D Lawson, D Cella, B El-Rayes, R Carlos	01/01/2022
Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. The Lancet. Oncology	DC Qian, T Kleber, B Brammer, KM Xu, JM Switchenko, JR Janopaul-Naylor, J Zhong, ML Yushak, RD Harvey, CM Paulos, DH Lawson, MK Khan, RR Kudchadkar, ZS Buchwald	12/01/2021
Melanoma Cell Intrinsic GABA_A Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity. International journal of radiation oncology, biology, physics	DA Pomeranz Krummel, TH Nasti, M Kaluzova, L Kallay, D Bhattacharya, JC Melms, B Izar, M Xu, A Burnham, T Ahmed, G Li, D Lawson, J Kowalski, Y Cao, JM Switchenko, D Ionascu, JM Cook, M Medvedovic, A Jenkins, MK Khan, S Sengupta	03/15/2021
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. Journal for immunotherapy of cancer	ZS Buchwald, TH Nasti, J Lee, CS Eberhardt, A Wieland, SJ Im, D Lawson, W Curran, R Ahmed, MK Khan	10/01/2020
Exosome-Containing Preparations From Postirradiated Mouse Melanoma Cells Delay Melanoma Growth In Vivo by a Natural Killer Cell-Dependent Mechanism. International journal of radiation oncology, biology, physics	KK Jella, TH Nasti, Z Li, DH Lawson, JM Switchenko, R Ahmed, WS Dynan, MK Khan	09/01/2020
Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. International journal of radiation oncology, biology, physics	DA Pomeranz Krummel, TH Nasti, B Izar, RH Press, M Xu, L Lowder, L Kallay, M Rupji, H Rosen, J Su, W Curran, J Olson, B Weinberg, M Schniederjan, S Neill, D Lawson, J Kowalski, MK Khan, S Sengupta	09/01/2020
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA dermatology	D Grossman, N Okwundu, EK Bartlett, MA Marchetti, M Othus, DG Coit, RI Hartman, SA Leachman, EG Berry, L Korde, SJ Lee, M Bar-Eli, M Berwick, T Bowles, EI Buchbinder, EM Burton, EY Chu, C Curiel-Lewandrowski, JA Curtis, A Daud, DC Deacon, LK Ferris, JE Gershenwald, KF Grossmann, S Hu-Lieskovan, J Hyngstrom, JM Jeter, RL Judson-Torres, KL Kendra, CC Kim, JM Kirkwood, DH Lawson, PD Leming, GV Long, AA Marghoob, JM Mehnert, ME Ming, KC Nelson, D Polsky, RA Scolyer, EA Smith, VK Sondak, MS Stark, JA Stein, JA Thompson, JF Thompson, SS Venna, ML Wei, SM Swetter	09/01/2020
Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery	C Jiang, DG Wallington, CJ Anker, DH Lawson, ML Yushak, RR Kudchadkar, A Tarhini, MK Khan	09/01/2020
20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment. Annals of translational medicine	S Chandrasekaran, DH Lawson	06/01/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. The oncologist	MA Bilen, DJ Martini, Y Liu, JM Shabto, JT Brown, M Williams, AI Khan, A Speak, C Lewis, H Collins, HT Kissick, BC Carthon, M Akce, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master	03/01/2020
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. Cancer	DJ Martini, MR Kline, Y Liu, JM Shabto, MA Williams, AI Khan, C Lewis, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, VA Master, MA Bilen	02/01/2020
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. Cardiovascular and interventional radiology	AO Levey, M Elsayed, DH Lawson, RM Ermentrout, RR Kudchadkar, ZL Bercu, ML Yushak, J Newsome, N Kokabi	02/01/2020
Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases. Science advances	S Tan, H Yang, S Xue, J Qiao, M Salarian, K Hekmatyar, Y Meng, R Mukkavilli, F Pu, OY Odubade, W Harris, Y Hai, ML Yushak, VM Morales-Tirado, P Mittal, PZ Sun, D Lawson, HE Grossniklaus, JJ Yang	02/01/2020
Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational new drugs	DJ Martini, Y Liu, JM Shabto, C Lewis, MR Kline, H Collins, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, VA Master, BF El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey, MA Bilen	12/01/2019
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC cancer	MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, H Kissick, BC Carthon, WL Shaib, OB Alese, CE Steuer, C Wu, DH Lawson, R Kudchadkar, VA Master, B El-Rayes, SS Ramalingam, TK Owonikoko, RD Harvey	08/29/2019
Automated RNA In Situ Hybridization for 18 High Risk Human Papilloma Viruses in Squamous Cell Carcinoma of the Head and Neck: Comparison With p16 Immunohistochemistry. Applied immunohistochemistry & molecular morphology : AIMM	B Drumheller, C Cohen, D Lawson, MT Siddiqui	02/01/2019
RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. Applied immunohistochemistry & molecular morphology : AIMM	CJ Roe, MT Siddiqui, D Lawson, C Cohen	02/01/2019
The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer	MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, HT Kissick, BC Carthon, WL Shaib, OB Alese, RN Pillai, CE Steuer, CS Wu, DH Lawson, RR Kudchadkar, BF El-Rayes, VA Master, SS Ramalingam, TK Owonikoko, RD Harvey	01/01/2019
T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer immunology, immunotherapy : CII	A Wieland, AO Kamphorst, NV Adsay, JJ Masor, J Sarmiento, TH Nasti, S Darko, DC Douek, Y Xue, WJ Curran, DH Lawson, R Ahmed	11/01/2018
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. Journal for immunotherapy of cancer	JI Clark, J Singh, MS Ernstoff, CD Lao, LE Flaherty, TF Logan, B Curti, SS Agarwala, B Taback, L Cranmer, J Lutzky, TL Luna, S Aung, DH Lawson	07/27/2018
Insights into the Psychology of Trauma Should Inform the Practice of Oncology. The oncologist	KC Lawson, DH Lawson	07/01/2018
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. Journal for immunotherapy of cancer	RJ Sullivan, MB Atkins, JM Kirkwood, SS Agarwala, JI Clark, MS Ernstoff, L Fecher, TF Gajewski, B Gastman, DH Lawson, J Lutzky, DF McDermott, KA Margolin, JM Mehnert, AC Pavlick, JM Richards, KM Rubin, W Sharfman, S Silverstein, CL Slingluff, VK Sondak, AA Tarhini, JA Thompson, WJ Urba, RL White, ED Whitman, FS Hodi, HL Kaufman	05/30/2018
Radiologic and Histopathologic Correlation of Different Growth Patterns of Metastatic Uveal Melanoma to the Liver. Ophthalmology	A Liao, P Mittal, DH Lawson, JJ Yang, E Szalai, HE Grossniklaus	04/01/2018
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular cell	R Lin, S Xia, C Shan, D Chen, Y Liu, X Gao, M Wang, HB Kang, Y Pan, S Liu, YR Chung, O Abdel-Wahab, T Merghoub, M Rossi, RR Kudchadkar, DH Lawson, FR Khuri, S Lonial, J Chen	03/15/2018
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC cancer	JS Zager, BR Gastman, S Leachman, RC Gonzalez, MD Fleming, LK Ferris, J Ho, AR Miller, RW Cook, KR Covington, K Meldi-Plasseraud, B Middlebrook, LH Kaminester, A Greisinger, SI Estrada, DM Pariser, LD Cranmer, JL Messina, JT Vetto, JD Wayne, KA Delman, DH Lawson, P Gerami	02/05/2018
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. Journal for immunotherapy of cancer	L Cafuir, D Lawson, N Desai, V Kesner, A Voloschin	01/30/2018
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma research	S Hallmeyer, R Gonzalez, DH Lawson, LD Cranmer, GP Linette, I Puzanov, B Taback, CL Cowey, A Ribas, GA Daniels, T Moore, GT Gibney, H Tawbi, E Whitman, G Lee, Y Mun, S Liu, O Hamid	12/01/2017
Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. American journal of clinical oncology	KR Patel, S Shoukat, DE Oliver, M Chowdhary, M Rizzo, DH Lawson, F Khosa, Y Liu, MK Khan	10/01/2017
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clinical cancer research : an official journal of the American Association for Cancer Research	LH Butterfield, F Zhao, S Lee, AA Tarhini, KA Margolin, RL White, MB Atkins, GI Cohen, TL Whiteside, JM Kirkwood, DH Lawson	09/01/2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry	L Zhao, J Fan, S Xia, Y Pan, S Liu, G Qian, Z Qian, HB Kang, JL Arbiser, BP Pollack, RR Kudchadkar, DH Lawson, M Rossi, O Abdel-Wahab, T Merghoub, HJ Khoury, FR Khuri, LH Boise, S Lonial, F Chen, J Chen, R Lin	06/16/2017
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of cancer research and clinical oncology	TM Atkinson, JL Hay, A Shoushtari, Y Li, DJ Paucar, SC Smith, RR Kudchadkar, A Doyle, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, GP Linette, TF Gajewski, J Lutzky, DH Lawson, CD Lao, PJ Flynn, MR Albertini, T Sato, K Lewis, B Marr, DH Abramson, MA Dickson, GK Schwartz, RD Carvajal	03/01/2017
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma management	MM Johnson, SA Leachman, LG Aspinwall, LD Cranmer, C Curiel-Lewandrowski, VK Sondak, CE Stemwedel, SM Swetter, J Vetto, T Bowles, RP Dellavalle, LJ Geskin, D Grossman, KF Grossmann, JE Hawkes, JM Jeter, CC Kim, JM Kirkwood, AR Mangold, F Meyskens, ME Ming, KC Nelson, M Piepkorn, BP Pollack, JK Robinson, AJ Sober, S Trotter, SS Venna, S Agarwala, R Alani, B Averbook, A Bar, M Becevic, N Box, W E Carson, PB Cassidy, SC Chen, EY Chu, DL Ellis, LK Ferris, DE Fisher, K Kendra, DH Lawson, PD Leming, KA Margolin, S Markovic, MC Martini, D Miller, D Sahni, WH Sharfman, J Stein, AJ Stratigos, A Tarhini, MH Taylor, OJ Wisco, MK Wong	03/01/2017
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism	S Xia, R Lin, L Jin, L Zhao, HB Kang, Y Pan, S Liu, G Qian, Z Qian, E Konstantakou, B Zhang, JT Dong, YR Chung, O Abdel-Wahab, T Merghoub, L Zhou, RR Kudchadkar, DH Lawson, HJ Khoury, FR Khuri, LH Boise, S Lonial, BH Lee, BP Pollack, JL Arbiser, J Fan, QY Lei, J Chen	02/07/2017
Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. American journal of clinical oncology	M Xing, HJ Prajapati, R Dhanasekaran, DH Lawson, N Kokabi, BR Eaton, HS Kim	02/01/2017
The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma research	HH Danish, KR Patel, JM Switchenko, TW Gillespie, J Jhaveri, M Chowdhary, M Abugideiri, KA Delman, DH Lawson, MK Khan	12/01/2016
Complete response to high-dose IL-2 and enhanced IFNγ+Th17 : TREG ratio in a melanoma patient. Melanoma research	ML Diller, RR Kudchadkar, KA Delman, DH Lawson, ML Ford	10/01/2016
BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma research	KR Patel, M Chowdhary, JM Switchenko, R Kudchadkar, DH Lawson, RJ Cassidy, RS Prabhu, MK Khan	08/01/2016
Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases. Ocular oncology and pathology	KM Halenda, RR Kudchadkar, DH Lawson, DD Kies, KE Zhelnin, AM Krasinskas, HE Grossniklaus	04/01/2016
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. The Journal of molecular diagnostics : JMD	KE Fisher, L Zhang, J Wang, GH Smith, S Newman, TM Schneider, RN Pillai, RR Kudchadkar, TK Owonikoko, SS Ramalingam, DH Lawson, KA Delman, BF El-Rayes, MM Wilson, HC Sullivan, AS Morrison, S Balci, NV Adsay, AA Gal, GL Sica, DF Saxe, KP Mann, CE Hill, FR Khuri, MR Rossi	03/01/2016
Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma research	DE Oliver, KR Patel, J Switchenko, D Parker, DH Lawson, KA Delman, RR Kudchadkar, MK Khan	02/01/2016
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. Journal for immunotherapy of cancer	A Amin, DH Lawson, AK Salama, HB Koon, T Guthrie, SS Thomas, SJ O'Day, MF Shaheen, B Zhang, S Francis, FS Hodi	01/01/2016
Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients. Journal of immunotherapy (Hagerstown, Md. : 1997)	ML Diller, RR Kudchadkar, KA Delman, DH Lawson, ML Ford	01/01/2016
Balancing Inflammation: The Link between Th17 and Regulatory T Cells. Mediators of inflammation	ML Diller, RR Kudchadkar, KA Delman, DH Lawson, ML Ford	01/01/2016
BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy. OncoTargets and therapy	M Chowdhary, KR Patel, HH Danish, DH Lawson, MK Khan	01/01/2016
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). Journal of clinical oncology : official journal of the American Society of Clinical Oncology	DH Lawson, S Lee, F Zhao, AA Tarhini, KA Margolin, MS Ernstoff, MB Atkins, GI Cohen, TL Whiteside, LH Butterfield, JM Kirkwood	12/01/2015
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-oncology	KR Patel, DH Lawson, RR Kudchadkar, BC Carthon, DE Oliver, D Okwan-Duodu, R Ahmed, MK Khan	10/01/2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell	HB Kang, J Fan, R Lin, S Elf, Q Ji, L Zhao, L Jin, JH Seo, C Shan, JL Arbiser, C Cohen, D Brat, HM Miziorko, E Kim, O Abdel-Wahab, T Merghoub, S Fröhling, C Scholl, P Tamayo, DA Barbie, L Zhou, BP Pollack, K Fisher, RR Kudchadkar, DH Lawson, G Sica, M Rossi, S Lonial, HJ Khoury, FR Khuri, BH Lee, TJ Boggon, C He, S Kang, J Chen	08/06/2015
Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. Journal of the American Academy of Dermatology	P Gerami, RW Cook, MC Russell, J Wilkinson, RN Amaria, R Gonzalez, S Lyle, GL Jackson, AJ Greisinger, CE Johnson, KM Oelschlager, JF Stone, DJ Maetzold, LK Ferris, JD Wayne, C Cooper, R Obregon, KA Delman, D Lawson	05/01/2015
The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma research	DE Oliver, KR Patel, D Parker, KA Delman, DH Lawson, RR Kudchadkar, MK Khan	04/01/2015
Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. American journal of clinical oncology	D Okwan-Duodu, BP Pollack, D Lawson, MK Khan	02/01/2015
Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research	P Gerami, RW Cook, J Wilkinson, MC Russell, N Dhillon, RN Amaria, R Gonzalez, S Lyle, CE Johnson, KM Oelschlager, GL Jackson, AJ Greisinger, D Maetzold, KA Delman, DH Lawson, JF Stone	01/01/2015
Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997)	JN Crosson, PW Laird, M Debiec, CS Bergstrom, DH Lawson, S Yeh	01/01/2015
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. American journal of clinical oncology	DM Marcus, M Lowe, MK Khan, DH Lawson, IR Crocker, JW Shelton, A Melton, N Maynard, KA Delman, GW Carlson, M Rizzo	12/01/2014
Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. Cancer research	J Deng, S Yuan, A Pennati, J Murphy, JH Wu, D Lawson, J Galipeau	08/01/2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA	RD Carvajal, JA Sosman, JF Quevedo, MM Milhem, AM Joshua, RR Kudchadkar, GP Linette, TF Gajewski, J Lutzky, DH Lawson, CD Lao, PJ Flynn, MR Albertini, T Sato, K Lewis, A Doyle, K Ancell, KS Panageas, M Bluth, C Hedvat, J Erinjeri, G Ambrosini, B Marr, DH Abramson, MA Dickson, JD Wolchok, PB Chapman, GK Schwartz	06/18/2014
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer journal (Sudbury, Mass.)	L Flaherty, O Hamid, G Linette, L Schuchter, S Hallmeyer, R Gonzalez, CL Cowey, A Pavlick, F Kudrik, B Curti, D Lawson, PB Chapman, K Margolin, A Ribas, D McDermott, K Flaherty, L Cranmer, FS Hodi, BM Day, R Linke, J Hainsworth	01/01/2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. Journal for immunotherapy of cancer	S Ravi, K Spencer, M Ruisi, N Ibrahim, JJ Luke, JA Thompson, K Shirai, D Lawson, H Bartell, R Kudchadkar, NT Gunter, JM Mehnert, EJ Lipson	01/01/2014
The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	D Musselman, EB Royster, M Wang, Q Long, LM Trimble, TK Mann, DS Graciaa, MD McNutt, NS Auyeung, L Oliver, DH Lawson, AH Miller	09/01/2013
Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. Journal of vascular and interventional radiology : JVIR	SM Piduru, DM Schuster, BJ Barron, R Dhanasekaran, DH Lawson, HS Kim	07/01/2012
Rising incidence of mucosal melanoma of the head and neck in the United States. Journal of skin cancer	DM Marcus, RP Marcus, RS Prabhu, TK Owonikoko, DH Lawson, J Switchenko, JJ Beitler	01/01/2012
Melanoma quality of life: pilot study using utility measurements. Archives of dermatology	SM King, P Bonaccorsi, S Bendeck, J Hadley, K Puttgen, PG Kolm, E Veledar, D Lawson, SC Chen	03/01/2011
Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms. Annals of surgical oncology	B Ghazi, GW Carlson, DR Murray, KW Gow, A Page, M Durham, DA Kooby, D Parker, L Rapkin, DH Lawson, KA Delman	09/01/2010
Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clinical trials (London, England)	SF Auyeung, Q Long, EB Royster, S Murthy, MD McNutt, D Lawson, A Miller, A Manatunga, DL Musselman	10/01/2009
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). Journal of immunotherapy (Hagerstown, Md. : 1997)	M Akhtari, EK Waller, DL Jaye, DH Lawson, R Ibrahim, NE Papadopoulos, ML Arellano	04/01/2009

Awards

Alpha Omega Alpha - VA Career Development Program Award
"Top Doctors" - Atlanta Magazine, 2009-2018

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

5	One star One star One star One star One star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/07/2025	Dr. Lawson was very professional and able to answer my questions. He is an excellent listener.
One star One star One star One star One star	05/06/2025	Dr. Lawson is awesome!
One star One star One star One star One star	04/25/2025	Always a good and thorough visit :)
One star One star One star One star One star	04/23/2025	Dr Lawson was very kind asked all about health issues and did not rush at all.
One star One star One star One star One star	04/15/2025	Dr Lawson seemed very thorough. He is a careful listener. I read the notes in MyChart from the visit and was surprised how much detail were in them. He's a very compassionate doctor.
One star One star One star One star One star	04/15/2025	My wife and I are very grateful for Dr. Lawson. He explains all the procedures/test and what is required and I appreciate his patience and kindness. He also has a very good team.
One star One star One star One star One star	03/04/2025	Dr Lawson was so caring, took lots of time with me and my husband
One star One star One star One star One star	03/01/2025	Good
One star One star One star One star One star	02/16/2025	Dr. Lawson was excellent.
One star One star One star One star One star	01/24/2025	Dr Lawson answered all of my questions and a way that was understandable.
One star One star One star One star One star	01/18/2025	Very nice
One star One star One star One star One star	01/14/2025	Dr Lawson is the epitome of the professional Doctor. He was patient, kind , knowledgeable, informative and caring during my visit. He included my wife in all aspects of my care. I would recommend him and Emory oncology center to everyone.
One star One star One star One star One star	01/07/2025	Everybody was very good.
One star One star One star One star One star	01/05/2025	Dr. Lawson was very professional and caring. He really listened to me.
One star One star One star One star One star	12/23/2024	Very good
One star One star One star One star One star	11/11/2024	Enjoyed conversation with Dr. Lawson I feel like he was generally concerned about his patience
One star One star One star One star One star	10/31/2024	Dr Lawson is always so understanding and willing to go the extra mile to make sure u understand and have all of your questions answered.
One star One star One star One star One star	10/20/2024	Dr Lawson took the time to research my medical history and was extraordinarily patient in explaining my options.
One star One star One star One star Empty star	10/01/2024	Dr. Lawson collected a lot of information, but provided no guidance on what to do next.
One star One star One star One star One star	09/26/2024	Dr Lawson is exceptionally good at listening to questions and giving clear explanations
One star One star One star One star One star	09/17/2024	I felt very good about Dr. Lawson! He checked me over thoroughly and we discussed my on going treatment that a layman could understand and all my questions and concerns were answered.
One star One star One star Empty star Empty star	07/26/2024	You only have one chance to make a good first impression. I had been looking forward to meeting Dr. Lawson. After waiting 6 weeks for the appointment, then another hour in the room after vitals had been taken, he came in distracted. Our discussion was interrupted a few times by his cell phone. He started going into the risk factors of the treatment he thought I should do but didn't explain how this treatment was decided upon. We were having a hard time communicating/ understanding the process. There was a resident In the room with us and she finally understood. She then proceeded to pull up on the computer paperwork concerning my condition.
One star One star One star One star One star	06/25/2024	Dr Lawson was very helpful in explaining everything to me in a way that I could understand.